Abstract
It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Keywords: IFN, ISGs, HCV, IL-28B, IFNL4, DAAs, innate immunity.
Current Drug Targets
Title:Role of Interferons in Chronic Hepatitis C Infection
Volume: 18 Issue: 7
Author(s): Carolina Scagnolari, Katia Monteleone, Giulia Cacciotti and Guido Antonelli*
Affiliation:
- Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Viale di Porta Tiburtina 28 – 00185 Rome,Italy
Keywords: IFN, ISGs, HCV, IL-28B, IFNL4, DAAs, innate immunity.
Abstract: It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Export Options
About this article
Cite this article as:
Scagnolari Carolina, Monteleone Katia, Cacciotti Giulia and Antonelli Guido*, Role of Interferons in Chronic Hepatitis C Infection, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450117666160201112632
DOI https://dx.doi.org/10.2174/1389450117666160201112632 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research The Effects of Combined Omega-3 Fatty Acids and Valproic Acid Supplementation on Symptoms of Borderline Personality Disorder: A Pilot Study
Current Psychopharmacology Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Biology of the Interleukin-9 Pathway and its Therapeutic Potential for the Treatment of Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry Meet Our Editorial Board Member
Medicinal Chemistry Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine
Current Genomics Induced Human Bone Marrow Stromal Cells Differentiate into Neural Cells by bFGF and Cocultured with Olfactory Ensheathing Cells
Current Stem Cell Research & Therapy Anti-adipogenic and Cytotoxic Effects of a New Compound from <i>Hartmannia rosea</i> G. Don
Current Pharmaceutical Analysis PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain
Current Pharmaceutical Design Ca2+ Signaling, Mitochondria and Cell Death
Current Molecular Medicine Metabotropic Glutamate Receptors Modulate Periaqueductal Grey Descending Analgesic System
Central Nervous System Agents in Medicinal Chemistry Dendritic Cell Vaccine and Cancer Treatment: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot Topic: Sepsis (Guest Editor: David E. Joyce)]
Current Drug Targets Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Patent Annotations
Recent Patents on Cardiovascular Drug Discovery